News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
330,515 Results
Type
Article (19815)
Company Profile (128)
Press Release (310572)
Section
Business (105308)
Career Advice (876)
Deals (18521)
Drug Delivery (93)
Drug Development (50718)
Employer Resources (79)
FDA (7663)
Job Trends (7731)
News (185727)
Policy (17316)
Tag
Academia (726)
Alliances (27812)
Alzheimer's disease (598)
Antibody-drug conjugate (ADC) (71)
Approvals (7648)
Artificial intelligence (108)
Bankruptcy (171)
Best Places to Work (5548)
Biosimilars (74)
Breast cancer (93)
Cancer (823)
Cardiovascular disease (79)
Career advice (708)
Cell therapy (122)
Clinical research (42249)
Collaboration (360)
Compensation (115)
COVID-19 (1086)
C-suite (97)
Data (836)
Diabetes (118)
Diagnostics (1766)
Drug pricing (102)
Earnings (38459)
Employer resources (73)
Events (48075)
Executive appointments (339)
FDA (8070)
Funding (241)
Gene therapy (110)
GLP-1 (536)
Government (1814)
Healthcare (5888)
Infectious disease (1147)
Inflammatory bowel disease (74)
Interviews (115)
IPO (7349)
Job creations (2432)
Job search strategy (646)
Layoffs (265)
Legal (4095)
Lung cancer (129)
Manufacturing (161)
Medical device (1957)
Medtech (1960)
Mergers & acquisitions (11332)
Metabolic disorders (406)
Neuroscience (838)
NextGen: Class of 2025 (2354)
Non-profit (908)
Northern California (860)
Obesity (260)
Opinion (182)
Patents (96)
People (33185)
Pharmaceutical (74)
Phase I (13218)
Phase II (17879)
Phase III (14362)
Pipeline (414)
Policy (84)
Postmarket research (1618)
Preclinical (4602)
Radiopharmaceuticals (158)
Rare diseases (195)
Real estate (3169)
Regulatory (12316)
Research institute (817)
Resumes & cover letters (138)
Southern California (804)
Startups (2006)
United States (8011)
Vaccines (236)
Weight loss (213)
Date
Today (72)
Last 7 days (322)
Last 30 days (1436)
Last 365 days (17457)
2025 (1671)
2024 (17673)
2023 (19639)
2022 (25874)
2021 (26643)
2020 (24877)
2019 (20064)
2018 (15594)
2017 (17258)
2016 (16208)
2015 (18804)
2014 (14793)
2013 (12556)
2012 (13486)
2011 (13823)
2010 (12739)
Location
Africa (407)
Asia (24739)
Australia (3180)
California (1994)
Canada (925)
China (235)
Colorado (84)
Connecticut (78)
Europe (50926)
Florida (324)
Illinois (204)
Indiana (145)
Japan (87)
Maryland (294)
Massachusetts (1679)
Minnesota (111)
New Jersey (780)
New York (578)
North Carolina (420)
Northern California (860)
Ohio (71)
Pennsylvania (466)
South America (605)
Southern California (804)
Texas (260)
Washington State (179)
330,515 Results for "sichuan kelun pharma".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Kelun-Biotech’s Product Tagitanlimab Approved for Marketing in Second Indication in Combination with Cisplatin and Gemcitabine For the First-line Treatment of Patients with recurrent or metastatic NPC
January 23, 2025
·
3 min read
Press Releases
Kelun-Biotech Announce Exclusive License Agreement For SKB378/HBM9378, an Anti-thymic Stromal Lymphopoietin (TSLP) Monoclonal Antibody (mAb).
January 13, 2025
·
4 min read
Drug Development
AACR: Merck, Kelun’s Anti-TROP2 ADC Shows Early Promise in Gastric Cancer
Merck and Kelun-Biotech’s antibody-drug conjugate achieved a 22% objective response rate and 80.5% disease control rate in heavily pretreated patients with gastric or gastroesophageal junction cancer.
April 10, 2024
·
2 min read
·
Tristan Manalac
Biotech Bay
CEO of Kelun-Biotech Dr. Micheal Ge delivered a presentation on The 42nd JPM Annual Healthcare Conference
The 42nd J.P. Morgan Annual Healthcare Conference 2024 is taking place on January 8-11 at San Fracisco, USA, members of Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. senior management team participated in the conference.
January 11, 2024
·
3 min read
Press Releases
Kelun-Biotech’s TROP2 ADC Sacituzumab tirumotecan (sac-TMT) Approved For Marketing By NMPA Of China For 2L+ Advanced or Metastatic TNBC
November 27, 2024
·
5 min read
Press Releases
Kelun-Biotech’s TROP2-ADC SKB264 (sac-TMT) Third NDA Accepted by NMPA, locally advanced or metastatic EGFR-mutant NSCLC
October 31, 2024
·
4 min read
Press Releases
Multiple Study Results of Kelun-Biotech’s TROP2-ADC SKB264 (sac-TMT) at 2024 CSCO Congress
September 30, 2024
·
7 min read
Kelun-Biotech’s TROP2-ADC SKB264 (sac-TMT) Second NDA Accepted by NPMA, locally advanced or metastatic EGFR-mutant NSCLC
August 20, 2024
·
5 min read
BioMidwest
Rafarma pharmaceutical updates: agreements with Shri Lanka pharmaceutical company Kelun Lifesciences (Pvt) Ltd and El Salvador University
Rafarma Pharmaceuticals - We are pleased to announce that Rapharma and its CEO Raivo Unt have entered into a preliminary agreement with Kelun Lifesciences Ltd, a pharmaceutical company based in Sri Lanka, on 17 November 2023.
December 11, 2023
·
3 min read
Press Releases
Three Study Results Abstracts From Kelun-Biotech’s TROP2-ADC SKB264 (sac-TMT) At 2024 ESMO Released Today
September 9, 2024
·
9 min read
1 of 33,052
Next
